19:05 , Oct 6, 2017 |  BC Week In Review  |  Company News

Camino receives $10.8M grant to treat addiction

Newco Camino Pharma LLC (San Diego, Calif.) said it received a $10.8 million, three-year grant from NIH's National Institute on Drug Abuse (NIDA) which will fund a deal with Sanford Burnham Prebys Medical Research Institute...
07:00 , May 26, 2016 |  BC Innovations  |  Targets & Mechanisms

Dissociating ketamine

For decades, researchers have struggled with the conundrum of how to exploit the antidepressant effects of ketamine without incurring its psychedelic effects. Now, a group from NIH and the University of Maryland has shown that...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Eli Lilly and Co, Denovo Biopharma deal

Eli Lilly granted Denovo exclusive, worldwide rights to develop and commercialize pomaglumetad (formerly LY2140023). Denovo will identify genetic biomarkers for a companion diagnostic to screen for patients who may benefit from the product. Denovo then...
08:00 , Feb 5, 2015 |  BC Innovations  |  Product R&D

Addex's allosterics

Allosteric modulators are slowly filling the clinical pipeline, but finding the right assays to discover and characterize them properly still confounds companies in the space. Addex Therapeutics Ltd. is going back to basics and forging...
07:00 , May 22, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction Metabotropic glutamate receptor subtype 2 (mGluR2; GRM2); mGluR3 (GRM3) In vitro and rat studies suggest positive allosteric modulators (PAMs) of both mGluR2 and mGluR3...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

ADX71149: Phase IIa data

Addex said top-line data from a double-blind, international Phase IIa trial evaluating twice-daily oral ADX71149 for 8 weeks as an adjunct to a selective serotonin reuptake inhibitor (SSRI) or a serotonin/norepinephrine reuptake inhibitor (SNRI) in...
01:14 , Feb 8, 2014 |  BC Extra  |  Clinical News

ADX71149 misses in Phase IIa for anxious depression

Addex Therapeutics Ltd. (SIX:ADXN) said top-line data from a Phase IIa trial evaluating ADX71149 to treat major depressive disorder (MDD) with anxiety symptoms do not support further development of the compound for anxious depression. In...
08:00 , Nov 11, 2013 |  BioCentury  |  Strategy

New York translation

Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche 's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

ADX71149: Completed Phase II enrollment

Addex said Johnson & Johnson's Janssen Pharmaceuticals Inc. unit completed enrollment of 120 MDD patients with anxiety symptoms in a double-blind, placebo-controlled, international Phase IIa trial evaluating 25-150 mg oral ADX71149 twice daily for 8...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...